IN8bio Inc Dossier - Source-backed chat

IN8bio Inc

INABNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.53

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $1.40Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $13.8M

Enterprise Value −$4M

Shares Outstanding 9.9M diluted

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

IN8bio is a clinical-stage biopharmaceutical company pioneering innovative gamma-delta (γδ) T cell therapies and γδ T cell engagers (TCE) for oncology and autoimmune diseases. The company's proprietary DeltEx platform has demonstrated highly encouraging clinical efficacy, notably doubling median progression-free survival (mPFS) to 13.0 months in glioblastoma (GBM) patients compared to 6.6 months for standard-of-care. While the company faces near-term financial constraints and has raised going concern doubts with a cash runway extending into April 2027, its low valuation relative to its scientific potential and upcoming clinical/regulatory milestones present an attractive risk-reward profile for speculative biotech investors.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets4 analysts · as of 18 Aug 2026

Low · most bearish analyst$4.00

Mean target$6.25

High · most bullish analyst$10.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The company fails to secure additional financing or strategic partnerships, forcing it to further delay or terminate its clinical programs. Regulatory feedback from the FDA requires larger, more expensive trials than anticipated, exacerbating cash burn and leading to severe shareholder dilution or operational shutdown.

Base CaseCentral scenario

The company successfully advances its lead program INB-100 for leukemia and secures positive regulatory feedback from the FDA regarding clinical pathways for its GBM programs (INB-200/400). It accesses the remaining milestone-based tranches of its private placement or secures a strategic partnership, extending its cash runway and resolving going concern uncertainties.

Bull CaseUpside scenario

Successful clinical development and regulatory approval of INB-100 in AML and the INB-600 platform (INB-619) in oncology/autoimmune diseases, supported by strategic partnerships and milestone-based funding, leading to substantial valuation expansion.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Differentiated γδ T cell and TCE platforms targeting both oncology and autoimmune diseases.
Compelling clinical data in GBM showing a 97% improvement in mPFS (13.0 months vs. 6.6 months SOC).
Strong pipeline progress with INB-100 demonstrating high durable response rates in high-risk AML patients.
Strategic shift toward high-value TCE programs (INB-600 platform) addressing large market opportunities.

Key Investment Risks

Going concern uncertainty with a cash runway extending only into April 2027.
High dependence on external capital markets or partnerships to fund late-stage clinical trials.
Clinical development risks inherent to early-stage oncology and cell therapy candidates.
Potential delays in clinical trial enrollment or regulatory approvals.

Thesis Invalidation Triggers

Inability to secure additional funding or strategic collaborations by late 2026.
Negative or ambiguous clinical data readouts from the INB-100 or GBM programs.
Unfavorable regulatory guidance from the FDA regarding registrational pathways.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.